Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics Inc (NQ: EWTX )

31.98 +0.03 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Recap: Edgewise Therapeutics Q2 Earnings
  Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
Via Benzinga
Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers
Via Benzinga
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Edgewise Therapeutics, Inc.
Via Business Wire
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
Recap: Edgewise Therapeutics Q1 Earnings
Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Edgewise Therapeutics Announces Proposed Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
From Edgewise Therapeutics, Inc.
Via Business Wire
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
From Edgewise Therapeutics
Via Business Wire
6 Blue-Chip Stocks to Sell Now
This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession. 
Via InvestorPlace
Edgewise Therapeutics Initiates Mid-Stage Muscular Dystrophies Study
Edgewise Therapeutics (NASDAQ: EWTX) announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker Muscular Dystrophy (BMD). 
Via Benzinga
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Analyst Ratings for Edgewise Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.